Profilo
Scott Oehrlein is an Independent Director at Sauvie, Inc. He was previously the Chief Operating Officer at VIVUS, Inc. from 2018 to 2019.
Prior to that, he was the Head-Primary Care Sales US at Novartis Pharmaceuticals Corp.
from 2012 to 2014 and the Vice President & Head-General Medicines Sales at Sanofi Corp.
from 2014 to 2017.
He also served as the Global Chief Operations Officer at Willow Biopharma, Inc. from 2017 to 2018.
Oehrlein received his undergraduate degree from Franklin & Marshall College.
Posizioni attive di Scott Oehrlein
| Società | Posizione | Inizio |
|---|
Precedenti posizioni note di Scott Oehrlein
| Società | Posizione | Fine |
|---|---|---|
| VIVUS, INC. | Direttore operativo | 31/10/2019 |
Willow Biopharma, Inc.
Willow Biopharma, Inc. Medical/Nursing ServicesHealth Services Provides therapeutic services | Direttore operativo | 01/04/2018 |
Sanofi Corp.
Sanofi Corp. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi Corp. is a biopharmaceutical company dedicated to improving health outcomes through innovative medicines, vaccines, and patient-centered care. The company is based in Bridgewater, NJ. The company offers a broad portfolio including prescription medicines across therapeutic areas such as immunology, neurology, oncology, rare diseases, cardiovascular disease, diabetes, and transplant, alongside an extensive range of vaccines protecting against infectious diseases like influenza, respiratory syncytial virus (RSV), dengue, and COVID-19. Sanofi emphasizes scientific innovation with a robust R&D pipeline comprising clinical-stage projects, including advanced therapies like bispecific antibodies, gene therapies, and mRNA vaccines. The company addresses complex conditions such as chronic graft-versus-host disease in transplant patients and rare blood disorders like immune thrombocytopenia purpura, having launched therapies in these areas. Sanofi collaborates with healthcare professionals, patient communities, advocacy groups, and governments to expand access, promote holistic care, and advance science. Social impact initiatives focus on health equity, inclusion, environmental factors affecting respiratory health, and responsible business practices. Sanofi provides resources for healthcare providers and patients, including prescribing information, patient support, and educational materials, and maintains transparent communication through media channels and regular updates on financial performance, regulatory approvals, and clinical trial progress. | Corporate Officer/Principal | 01/06/2017 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Corporate Officer/Principal | 01/04/2014 |
Formazione di Scott Oehrlein
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
VIVUS, Inc.
VIVUS, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and commercializes next-generation therapies | Health Technology |
Franklin & Marshall College
Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Health Technology |
Sanofi Corp.
Sanofi Corp. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi Corp. is a biopharmaceutical company dedicated to improving health outcomes through innovative medicines, vaccines, and patient-centered care. The company is based in Bridgewater, NJ. The company offers a broad portfolio including prescription medicines across therapeutic areas such as immunology, neurology, oncology, rare diseases, cardiovascular disease, diabetes, and transplant, alongside an extensive range of vaccines protecting against infectious diseases like influenza, respiratory syncytial virus (RSV), dengue, and COVID-19. Sanofi emphasizes scientific innovation with a robust R&D pipeline comprising clinical-stage projects, including advanced therapies like bispecific antibodies, gene therapies, and mRNA vaccines. The company addresses complex conditions such as chronic graft-versus-host disease in transplant patients and rare blood disorders like immune thrombocytopenia purpura, having launched therapies in these areas. Sanofi collaborates with healthcare professionals, patient communities, advocacy groups, and governments to expand access, promote holistic care, and advance science. Social impact initiatives focus on health equity, inclusion, environmental factors affecting respiratory health, and responsible business practices. Sanofi provides resources for healthcare providers and patients, including prescribing information, patient support, and educational materials, and maintains transparent communication through media channels and regular updates on financial performance, regulatory approvals, and clinical trial progress. | Health Technology |
Willow Biopharma, Inc.
Willow Biopharma, Inc. Medical/Nursing ServicesHealth Services Provides therapeutic services | Health Services |
















